Pharmaceutical giant Johnson & Johnson (JNJ) has filed a lawsuit against a US government agency over a dispute concerning the 340B Drug Pricing Program. J&J argues that the program has been exploited by entities not intended as beneficiaries, leading to abuses that undermine patient benefits. The lawsuit centers around J&J’s proposed rebate-based pricing model, which aims to improve program transparency and curb duplicate discounting. However, the government agency responsible for overseeing the program, HRSA, has resisted the plan, leading to the legal action.